Literature DB >> 27771773

Case-control study of candidate gene methylation and adenomatous polyp formation.

M Alexander1,2, J B Burch3,4,5, S E Steck1,2, C-F Chen6, T G Hurley1, P Cavicchia1,2,7, N Shivappa1,2, J Guess1,2, H Zhang8, S D Youngstedt9, K E Creek10, S Lloyd11, K Jones6, J R Hébert1,2,12.   

Abstract

PURPOSE: Colorectal cancer (CRC) is one of the most common and preventable forms of cancer but remains the second leading cause of cancer-related death. Colorectal adenomas are precursor lesions that develop in 70-90 % of CRC cases. Identification of peripheral biomarkers for adenomas would help to enhance screening efforts. This exploratory study examined the methylation status of 20 candidate markers in peripheral blood leukocytes and their association with adenoma formation.
METHODS: Patients recruited from a local endoscopy clinic provided informed consent and completed an interview to ascertain demographic, lifestyle, and adenoma risk factors. Cases were individuals with a histopathologically confirmed adenoma, and controls included patients with a normal colonoscopy or those with histopathological findings not requiring heightened surveillance (normal biopsy, hyperplastic polyp). Methylation-specific polymerase chain reaction was used to characterize candidate gene promoter methylation. Odds ratios (ORs) and 95 % confidence intervals (95% CIs) were calculated using unconditional multivariable logistic regression to test the hypothesis that candidate gene methylation differed between cases and controls, after adjustment for confounders.
RESULTS: Complete data were available for 107 participants; 36 % had adenomas (men 40 %, women 31 %). Hypomethylation of the MINT1 locus (OR 5.3, 95% CI 1.0-28.2) and the PER1 (OR 2.9, 95% CI 1.1-7.7) and PER3 (OR 11.6, 95% CI 1.6-78.5) clock gene promoters was more common among adenoma cases. While specificity was moderate to high for the three markers (71-97 %), sensitivity was relatively low (18-45 %).
CONCLUSION: Follow-up of these epigenetic markers is suggested to further evaluate their utility for adenoma screening or surveillance.

Entities:  

Keywords:  Adenomatous polyp; Circadian rhythm; Colorectal cancer; Screening tests

Mesh:

Year:  2016        PMID: 27771773      PMCID: PMC5288296          DOI: 10.1007/s00384-016-2688-1

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  90 in total

Review 1.  Adjusting for multiple testing--when and how?

Authors:  R Bender; S Lange
Journal:  J Clin Epidemiol       Date:  2001-04       Impact factor: 6.437

2.  CpG island methylation in aberrant crypt foci of the colorectum.

Authors:  Annie On-On Chan; Russell R Broaddus; Patrick S Houlihan; Jean-Pierre J Issa; Stanley R Hamilton; Asif Rashid
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

3.  CpG island methylation in colorectal adenomas.

Authors:  A Rashid; L Shen; J S Morris; J P Issa; S R Hamilton
Journal:  Am J Pathol       Date:  2001-09       Impact factor: 4.307

4.  Sporadic colorectal cancers with microsatellite instability and their possible origin in hyperplastic polyps and serrated adenomas.

Authors:  N J Hawkins; R L Ward
Journal:  J Natl Cancer Inst       Date:  2001-09-05       Impact factor: 13.506

5.  CpG island methylator phenotype in colorectal cancer.

Authors:  M Toyota; N Ahuja; M Ohe-Toyota; J G Herman; S B Baylin; J P Issa
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

6.  Dietary exposures and oral precancerous lesions in Srikakulam District, Andhra Pradesh, India.

Authors:  James R Hebert; Prakash C Gupta; Ramesh B Bhonsle; Hemali Mehta; Wei Zheng; Maureen Sanderson; Jane Teas
Journal:  Public Health Nutr       Date:  2002-04       Impact factor: 4.022

7.  Cancer screening estimates for U.S. metropolitan areas.

Authors:  David E Nelson; Julie Bolen; Stephen Marcus; Henry E Wells; Helen Meissner
Journal:  Am J Prev Med       Date:  2003-05       Impact factor: 5.043

8.  Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence.

Authors:  Sidney Winawer; Robert Fletcher; Douglas Rex; John Bond; Randall Burt; Joseph Ferrucci; Theodore Ganiats; Theodore Levin; Steven Woolf; David Johnson; Lynne Kirk; Scott Litin; Clifford Simmang
Journal:  Gastroenterology       Date:  2003-02       Impact factor: 22.682

9.  Loss of IGF2 imprinting: a potential marker of colorectal cancer risk.

Authors:  Hengmi Cui; Marcia Cruz-Correa; Francis M Giardiello; David F Hutcheon; David R Kafonek; Sheri Brandenburg; Yiqian Wu; Xiaobing He; Neil R Powe; Andrew P Feinberg
Journal:  Science       Date:  2003-03-14       Impact factor: 47.728

10.  CpG island methylation is a common finding in colorectal cancer cell lines.

Authors:  C M Suter; M Norrie; S L Ku; K F Cheong; I Tomlinson; R L Ward
Journal:  Br J Cancer       Date:  2003-02-10       Impact factor: 7.640

View more
  2 in total

1.  Telomere length and genetics are independent colorectal tumour risk factors in an evaluation of biomarkers in normal bowel.

Authors:  Ceres Fernandez-Rozadilla; Christiana Kartsonaki; Connor Woolley; Michael McClellan; Deb Whittington; Gareth Horgan; Simon Leedham; Skirmantas Kriaucionis; James East; Ian Tomlinson
Journal:  Br J Cancer       Date:  2018-02-13       Impact factor: 7.640

2.  Multiple gene-specific DNA methylation in blood leukocytes and colorectal cancer risk: a case-control study in China.

Authors:  Yupeng Liu; Yibaina Wang; Fulan Hu; Hongru Sun; Zuoming Zhang; Xuan Wang; Xiang Luo; Lin Zhu; Rong Huang; Yan Li; Guangxiao Li; Xia Li; Shangqun Lin; Fan Wang; Yanhong Liu; Jiesheng Rong; Huiping Yuan; Yashuang Zhao
Journal:  Oncotarget       Date:  2017-05-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.